New hope for rare fever disorder: drug targets stubborn cases
NCT ID NCT06666335
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study tests whether anakinra (Kineret), a daily injection, can reduce monthly attacks in Chinese patients with Familial Mediterranean Fever (FMF) who do not respond to standard colchicine treatment. Three patients aged 2 years and older will receive anakinra for 6 months, with researchers tracking the number of fever and pain episodes. The goal is to see if this drug can safely control the disease in this hard-to-treat group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- anakinra (Kineret)
- What this could lead to
- If successful, anakinra could offer a new treatment option for Chinese patients with colchicine-resistant FMF, reducing painful attacks.
- What could go wrong
- This is a very small study (only 3 patients), so results may not apply broadly. Anakinra is already approved for other conditions, but its safety and efficacy in this specific population are still being confirmed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAMILIAL MEDITERRANEAN FEVER (FMF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which exercise focus works best for kids with rheumatic conditions?
- Real-World drug check for FMF patients
- Can a quick skin scan reveal hidden inflammation in arthritis?
- Can a smartphone app unlock the link between infections and FMF attacks?
- Scientists seek genetic clues to mysterious fever diseases